Eli Lilly, the pharmaceutical giant, has unveiled a plan to invest $27 billion in new drug manufacturing facilities across the United States, aiming to bolster domestic production amid potential tariffs and trade policy changes. This significant investment includes the establishment of four new manufacturing sites, expected to create thousands of high-wage jobs. In total, Lilly plans to double its U.S. manufacturing investment since 2020, with overall expenditures exceeding $50 billion. The move reflects growing pressure on pharmaceutical companies to bring production back to American soil as political and economic conditions evolve.